{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:07:30Z","timestamp":1767143250899,"version":"build-2238731810"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Statutory Activity of Jagiellonian University Medical College"},{"name":"Statutory Activity of Maj Institute of Pharmacology Polish Academy of Sciences"},{"name":"project Prokog, European Fund of Regional Development","award":["UGA POIG.01.03.01-12-063\/09-00"],"award-info":[{"award-number":["UGA POIG.01.03.01-12-063\/09-00"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s43440-025-00713-w","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T23:51:39Z","timestamp":1741650699000},"page":"689-702","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Compound PZ-1262, a 4-isoquinoline-sulfonamide analog of Brexpiprazole, produces potential antidepressant, anxiolytic and procognitive effects in rodent models"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9606-5228","authenticated-orcid":false,"given":"Anna","family":"Partyka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2250-2995","authenticated-orcid":false,"given":"Joanna","family":"Go\u0142\u0119biowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-2360","authenticated-orcid":false,"given":"Krzysztof","family":"Marciniec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7940-9500","authenticated-orcid":false,"given":"Vittorio","family":"Canale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3691-5627","authenticated-orcid":false,"given":"Wojciech","family":"Tryba\u0142a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0756-7232","authenticated-orcid":false,"given":"Grzegorza","family":"Sata\u0142a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2264-251X","authenticated-orcid":false,"given":"Katarzyna","family":"Grychowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5388-1214","authenticated-orcid":false,"given":"Magdalena","family":"Jastrz\u0119bska-Wi\u0119sek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1417-6333","authenticated-orcid":false,"given":"Andrzej J.","family":"Bojarski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2424-8348","authenticated-orcid":false,"given":"Agnieszka","family":"Nikiforuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1226-1721","authenticated-orcid":false,"given":"W\u0142adys\u0142awa A.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2383-3278","authenticated-orcid":false,"given":"Anna","family":"Weso\u0142owska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6192-8721","authenticated-orcid":false,"given":"Pawe\u0142","family":"Zajdel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3974-8553","authenticated-orcid":false,"given":"Piotr","family":"Popik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"713_CR1","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, \u00d6rey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet. 2013;382:951\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(13)60733-3.","journal-title":"Lancet"},{"key":"713_CR2","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.ejmech.2018.01.002","volume":"145","author":"P Zajdel","year":"2018","unstructured":"Zajdel P, Kos T, Marciniec K, Sata\u0142a G, Canale V, Kami\u0144ski K, et al. Novel multi-target azinesulfonamides of Cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects. Eur J Med Chem. 2018;145:790\u2013804. https:\/\/doi.org\/10.1016\/j.ejmech.2018.01.002.","journal-title":"Eur J Med Chem"},{"key":"713_CR3","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00213-011-2247-y","volume":"216","author":"A Newman-Tancredi","year":"2011","unstructured":"Newman-Tancredi A, Kleven MS. Comparative Pharmacology of antipsychotics possessing combined dopamine D 2 and serotonin 5-HT 1A receptor properties. Psychopharmacology. 2011;216:451\u201373. https:\/\/doi.org\/10.1007\/s00213-011-2247-y.","journal-title":"Psychopharmacology"},{"key":"713_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.bbr.2014.09.040","volume":"285","author":"Y Oyamada","year":"2015","unstructured":"Oyamada Y, Horiguchi M, Rajagopal L, Miyauchi M, Meltzer HY. Combined serotonin (5-HT)1A agonism, 5-HT2A and dopamine D2 receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats. Behav Brain Res. 2015;285:165\u201375. https:\/\/doi.org\/10.1016\/j.bbr.2014.09.040.","journal-title":"Behav Brain Res"},{"key":"713_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40263-023-01014-7","volume":"37","author":"ALW Smith","year":"2023","unstructured":"Smith ALW, Harmer CJ, Cowen PJ, Murphy SE. The serotonin 1A (5-HT1A) receptor as a Pharmacological target in depression. CNS Drugs. 2023;37:571\u201385. https:\/\/doi.org\/10.1007\/s40263-023-01014-7.","journal-title":"CNS Drugs"},{"key":"713_CR6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40263-013-0071-0","volume":"27","author":"P Celada","year":"2013","unstructured":"Celada P, Bortolozzi A, Artigas F. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs. 2013;27:703\u201316. https:\/\/doi.org\/10.1007\/s40263-013-0071-0.","journal-title":"CNS Drugs"},{"key":"713_CR7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1515\/revneuro-2014-0005","volume":"25","author":"A Nikiforuk","year":"2014","unstructured":"Nikiforuk A. The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia. Rev Neurosci. 2014;25:367\u201382. https:\/\/doi.org\/10.1515\/revneuro-2014-0005.","journal-title":"Rev Neurosci"},{"key":"713_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.pbb.2010.11.009","volume":"99","author":"DC Goff","year":"2011","unstructured":"Goff DC, Hill M, Barch D. The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav. 2011;99:245\u201353. https:\/\/doi.org\/10.1016\/j.pbb.2010.11.009.","journal-title":"Pharmacol Biochem Behav"},{"key":"713_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00213-009-1521-8","volume":"205","author":"AI Abbas","year":"2009","unstructured":"Abbas AI, Hedlund PB, Huang X-P, Tran TB, Meltzer HY, Roth BL. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology. 2009;205:119\u201328. https:\/\/doi.org\/10.1007\/s00213-009-1521-8.","journal-title":"Psychopharmacology"},{"key":"713_CR10","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.neuropharm.2008.09.014","volume":"56","author":"J Shelton","year":"2009","unstructured":"Shelton J, Bonaventure P, Li X, Yun S, Lovenberg T, Dugovic C. 5-HT7 receptor deletion enhances REM sleep suppression induced by selective serotonin reuptake inhibitors, but not by direct stimulation of 5-HT1A receptor. Neuropharmacology. 2009;56:448\u201354. https:\/\/doi.org\/10.1016\/j.neuropharm.2008.09.014.","journal-title":"Neuropharmacology"},{"key":"713_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.pbb.2012.05.012","volume":"102","author":"JM Monti","year":"2012","unstructured":"Monti JM, Leopoldo M, Jantos H, Lagos P. Microinjection of the 5-HT7 receptor antagonist SB-269970 into the rat brainstem and basal forebrain: Site-dependent effects on REM sleep. Pharmacol Biochem Behav. 2012;102:373\u201380. https:\/\/doi.org\/10.1016\/j.pbb.2012.05.012.","journal-title":"Pharmacol Biochem Behav"},{"key":"713_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2174\/187152706784111551","volume":"5","author":"L Leriche","year":"2006","unstructured":"Leriche L, Bezard E, Gross C, Guillin O, Foll B, Diaz J, et al. The dopamine D3 receptor: A therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord - Drug Targets. 2006;5:25\u201343. https:\/\/doi.org\/10.2174\/187152706784111551.","journal-title":"CNS Neurol Disord - Drug Targets"},{"key":"713_CR13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00213-014-3459-8","volume":"231","author":"J Brosda","year":"2014","unstructured":"Brosda J, Jantschak F, Pertz HH. \u03b12-Adrenoceptors are targets for antipsychotic drugs. Psychopharmacology. 2014;231:801\u201312. https:\/\/doi.org\/10.1007\/s00213-014-3459-8.","journal-title":"Psychopharmacology"},{"key":"713_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1092852915000954","volume":"21","author":"SM Stahl","year":"2016","unstructured":"Stahl SM. Mechanism of action of Brexpiprazole: comparison with Aripiprazole. CNS Spectr. 2016;21:1\u20136. https:\/\/doi.org\/10.1017\/S1092852915000954.","journal-title":"CNS Spectr"},{"key":"713_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejmech.2012.11.042","volume":"60","author":"P Zajdel","year":"2013","unstructured":"Zajdel P, Marciniec K, Ma\u015blankiewicz A, Grychowska K, Sata\u0142a G, Duszy\u0144ska B, et al. Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of Aripiprazole targeting serotonin 5-HT\u2081A\/5-HT\u2082A\/5-HT\u2087 and dopamine D\u2082\/D\u2083 receptors. Eur J Med Chem. 2013;60:42\u201350. https:\/\/doi.org\/10.1016\/j.ejmech.2012.11.042.","journal-title":"Eur J Med Chem"},{"key":"713_CR16","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1021\/acsmedchemlett.6b00056","volume":"7","author":"P Zajdel","year":"2016","unstructured":"Zajdel P, Marciniec K, Sata\u0142a G, Canale V, Kos T, Partyka A, et al. N 1-Azinylsulfonyl-1 H -indoles: 5-HT6 receptor antagonists with procognitive and Antidepressant-Like properties. ACS Med Chem Lett. 2016;7:618\u201322. https:\/\/doi.org\/10.1021\/acsmedchemlett.6b00056.","journal-title":"ACS Med Chem Lett"},{"key":"713_CR17","doi-asserted-by":"publisher","unstructured":"Blicharz-Futera K, Kami\u0144ski M, Grychowska K, Canale V, Zajdel P. Current development in sulfonamide derivatives to enable CNS-drug discovery. Bioorg Chem. 2025;156. https:\/\/doi.org\/10.1016\/j.bioorg.2024.108076.","DOI":"10.1016\/j.bioorg.2024.108076"},{"key":"713_CR18","doi-asserted-by":"publisher","first-page":"8717","DOI":"10.1021\/acs.jmedchem.8b00828","volume":"61","author":"R Kurczab","year":"2018","unstructured":"Kurczab R, Canale V, Sataa G, Zajdel P, Bojarski AJ. Amino acid hot spots of halogen bonding: A combined theoretical and experimental case study of the 5-HT7 receptor. J Med Chem. 2018;61:8717\u201333. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b00828.","journal-title":"J Med Chem"},{"key":"713_CR19","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1016\/j.bmc.2017.04.046","volume":"25","author":"A Partyka","year":"2017","unstructured":"Partyka A, Kurczab R, Canale V, Sata\u0142a G, Marciniec K, Pasierb A, et al. The impact of the halogen bonding on D2 and 5-HT1A \/5-HT7 receptor activity of azinesulfonamides of 4-[(2-ethyl)piperidinyl-1-yl]phenylpiperazines with antipsychotic and antidepressant properties. Bioorg Med Chem. 2017;25:3638\u201348. https:\/\/doi.org\/10.1016\/j.bmc.2017.04.046.","journal-title":"Bioorg Med Chem"},{"key":"713_CR20","doi-asserted-by":"publisher","unstructured":"Canale V, Tryba\u0142a W, Chaumont-Dubel S, Koczurkiewicz-Adamczyk P, Sata\u0142a G, Bento O, et al. 1-(Arylsulfonyl-isoindol-2-yl)piperazines as 5-HT6R antagonists: mechanochemical synthesis, in vitro Pharmacological properties and glioprotective activity. Biomolecules. 2023;13. https:\/\/doi.org\/10.3390\/biom13010012.","DOI":"10.3390\/biom13010012"},{"key":"713_CR21","doi-asserted-by":"publisher","unstructured":"Singh JK, Solanki A. Comparative in-vitro intrinsic clearance of Imipramine in multiple species liver microsomes: human, rat, mouse and dog. J Drug Metab Toxicol. 2012;3. https:\/\/doi.org\/10.4172\/2157-7609.1000126.","DOI":"10.4172\/2157-7609.1000126"},{"key":"713_CR22","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1111\/jphp.12305","volume":"66","author":"A Partyka","year":"2014","unstructured":"Partyka A, Jarosz J, Wasik A, Jastrz\u0119bska-Wi\u0119sek M, Zag\u00f3rska A, Paw\u0142owski M, et al. Novel tricyclic[2,1-f]theophylline derivatives of LCAP with activity in mouse models of affective disorders. J Pharm Pharmacol. 2014;66:1755\u201362. https:\/\/doi.org\/10.1111\/jphp.12305.","journal-title":"J Pharm Pharmacol"},{"key":"713_CR23","doi-asserted-by":"publisher","first-page":"13279","DOI":"10.1021\/acs.jmedchem.1c00224","volume":"64","author":"P Zajdel","year":"2021","unstructured":"Zajdel P, Grychowska K, Mogilski S, Kurczab R, Sata\u0142a G, Bugno R, et al. Structure-Based design and optimization of FPPQ, a Dual-Acting 5-HT3and 5-HT6Receptor antagonist with antipsychotic and procognitive properties. J Med Chem. 2021;64:13279\u201398. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00224.","journal-title":"J Med Chem"},{"key":"713_CR24","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1016\/j.bmc.2015.04.026","volume":"23","author":"A Czopek","year":"2015","unstructured":"Czopek A, Ko\u0142aczkowski M, Bucki A, Byrtus H, Paw\u0142owski M, Kazek G, et al. Novel Spirohydantoin derivative as a potent multireceptor-active antipsychotic and antidepressant agent. Bioorg Med Chem. 2015;23:3436\u201347. https:\/\/doi.org\/10.1016\/j.bmc.2015.04.026.","journal-title":"Bioorg Med Chem"},{"key":"713_CR25","first-page":"327","volume":"229","author":"RD Porsolt","year":"1977","unstructured":"Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Th\u00e9rapie. 1977;229:327\u201336.","journal-title":"Arch Int Pharmacodyn Th\u00e9rapie"},{"key":"713_CR26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1124\/jpet.114.213793","volume":"350","author":"K Maeda","year":"2014","unstructured":"Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350:589\u2013604. https:\/\/doi.org\/10.1124\/jpet.114.213793.","journal-title":"J Pharmacol Exp Ther"},{"key":"713_CR27","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1021\/jm401895u","volume":"57","author":"M Ko\u0142aczkowski","year":"2014","unstructured":"Ko\u0142aczkowski M, Marcinkowska M, Bucki A, Paw\u0142owski M, Mitka K, Ja\u015bkowska J, et al. Novel arylsulfonamide derivatives with 5-HT 6 \/5-HT 7 receptor antagonism targeting behavioral and psychological symptoms of dementia. J Med Chem. 2014;57:4543\u201357. https:\/\/doi.org\/10.1021\/jm401895u.","journal-title":"J Med Chem"},{"key":"713_CR28","first-page":"299","volume":"45","author":"K Go\u0142embiowska","year":"1993","unstructured":"Go\u0142embiowska K, Wedzony K. Enhancement by Ipsapirone of dopamine release in the rat striatum. Pol J Pharmacol. 1993;45:299\u2013308.","journal-title":"Pol J Pharmacol"},{"key":"713_CR29","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/BF00589908","volume":"99","author":"A Plaznik","year":"1989","unstructured":"Plaznik A, Stefanski R, Kostowski W. Interaction between accumbens D1 and D2 receptors regulating rat locomotor activity. Psychopharmacology. 1989;99:558\u201362. https:\/\/doi.org\/10.1007\/BF00589908.","journal-title":"Psychopharmacology"},{"key":"713_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1055\/s-2007-979350","volume":"31","author":"M Geyer","year":"1998","unstructured":"Geyer M. Behavioral studies of hallucinogenic drugs in animals: implications for schizophrenia research. Pharmacopsychiatry. 1998;31:73\u20139. https:\/\/doi.org\/10.1055\/s-2007-979350.","journal-title":"Pharmacopsychiatry"},{"key":"713_CR31","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00213-003-1549-0","volume":"170","author":"GA Higgins","year":"2003","unstructured":"Higgins GA, Enderlin M, Haman M, Fletcher PJ. The 5-HT2A receptor antagonist M100,907 attenuates motor and impulsive-type behaviours produced by NMDA receptor antagonism. Psychopharmacology. 2003;170:309\u201319. https:\/\/doi.org\/10.1007\/s00213-003-1549-0.","journal-title":"Psychopharmacology"},{"key":"713_CR32","doi-asserted-by":"publisher","unstructured":"Millan MJ. Dual- and Triple-Acting Agents for Treating Core and Co-morbid Symptoms of Major Depression: Novel Concepts, New Drugs. Neurotherapeutics. 2009;6:53\u201377. https:\/\/doi.org\/10.1016\/j.nurt.2008.10.039","DOI":"10.1016\/j.nurt.2008.10.039"},{"key":"713_CR33","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40263-015-0236-0","volume":"29","author":"A Nikiforuk","year":"2015","unstructured":"Nikiforuk A. Targeting the serotonin 5-HT7 receptor in the search for treatments for CNS disorders: rationale and progress to date. CNS Drugs. 2015;29:265\u201375. https:\/\/doi.org\/10.1007\/s40263-015-0236-0.","journal-title":"CNS Drugs"},{"key":"713_CR34","unstructured":"Otsuka. Abilify (aripiprazole) tablets, for oral use. Prescribing Information n.d. https:\/\/www.otsuka-us.com\/media\/static\/Abilify-PI.pdf; Revised 06.2024"},{"key":"713_CR35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00213-009-1583-7","volume":"206","author":"M Bourin","year":"2009","unstructured":"Bourin M, Chenu F, Prica C, Hasco\u00ebt M. Augmentation effect of combination therapy of Aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology. 2009;206:97\u2013107. https:\/\/doi.org\/10.1007\/s00213-009-1583-7.","journal-title":"Psychopharmacology"},{"key":"713_CR36","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1254\/jphs.08201SC","volume":"108","author":"J Kamei","year":"2008","unstructured":"Kamei J, Miyata S, Sunohara T, Kamei A, Shimada M, Ohsawa M. Potentiation of the antidepressant-like effect of Fluoxetine by Aripiprazole in the mouse tail suspension test. J Pharmacol Sci. 2008;108:381\u20134. https:\/\/doi.org\/10.1254\/jphs.08201SC.","journal-title":"J Pharmacol Sci"},{"key":"713_CR37","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1177\/02698811231211228","volume":"37","author":"N Gottlieb","year":"2023","unstructured":"Gottlieb N, Li TY, Young AH, Stokes PRA. The 5-HT7 receptor system as a treatment target for mood and anxiety disorders: A systematic review. J Psychopharmacol. 2023;37:1167\u201381. https:\/\/doi.org\/10.1177\/02698811231211228.","journal-title":"J Psychopharmacol"},{"key":"713_CR38","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/J.NEUROPHARM.2006.04.017","volume":"51","author":"A Weso\u0142owska","year":"2006","unstructured":"Weso\u0142owska A, Nikiforuk A, Stachowicz K, Tatarczy\u0144ska E. Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology. 2006;51:578\u201386. https:\/\/doi.org\/10.1016\/J.NEUROPHARM.2006.04.017.","journal-title":"Neuropharmacology"},{"key":"713_CR39","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.bbr.2018.11.019","volume":"359","author":"J Maxwell","year":"2019","unstructured":"Maxwell J, Gleason SD, Falcone J, Svensson K, Balcer OM, Li X, et al. Effects of 5-HT 7 receptor antagonists on behaviors of mice that detect drugs used in the treatment of anxiety, depression, or schizophrenia. Behav Brain Res. 2019;359:467\u201373. https:\/\/doi.org\/10.1016\/j.bbr.2018.11.019.","journal-title":"Behav Brain Res"},{"key":"713_CR40","doi-asserted-by":"publisher","first-page":"108099","DOI":"10.1016\/j.neuropharm.2020.108099","volume":"177","author":"MJ Millan","year":"2020","unstructured":"Millan MJ, Dekeyne A, Gobert A, Brocco M, Mannoury la Cour C, Ortuno JC, et al. Dual-acting agents for improving cognition and real-world function in Alzheimer\u2019s disease: focus on 5-HT6 and D3 receptors as hubs. Neuropharmacology. 2020;177:108099. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108099.","journal-title":"Neuropharmacology"},{"key":"713_CR41","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1021\/acschemneuro.6b00090","volume":"7","author":"K Grychowska","year":"2016","unstructured":"Grychowska K, Sata\u0142a G, Kos T, Partyka A, Colacino E, Chaumont-Dubel S, et al. Novel 1 H -Pyrrolo[3,2- C ]quinoline based 5-HT 6 receptor antagonists with potential application for the treatment of cognitive disorders associated with Alzheimer\u2019s disease. ACS Chem Neurosci. 2016;7:972\u201383. https:\/\/doi.org\/10.1021\/acschemneuro.6b00090.","journal-title":"ACS Chem Neurosci"},{"key":"713_CR42","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1021\/acs.jmedchem.0c02009","volume":"64","author":"D Vanda","year":"2021","unstructured":"Vanda D, Canale V, Chaumont-Dubel S, Kurczab R, Sata\u0142a G, Koczurkiewicz-Adamczyk P, et al. Imidazopyridine-Based 5-HT 6 receptor neutral antagonists: impact of N 1 -Benzyl and N 1 -Phenylsulfonyl fragments on different receptor conformational States. J Med Chem. 2021;64:1180\u201396. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c02009.","journal-title":"J Med Chem"},{"key":"713_CR43","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.schres.2024.09.030","volume":"274","author":"F de Beer","year":"2024","unstructured":"de Beer F, Wijnen B, Wouda L, Koops S, Gangadin S, Veling W, et al. Antipsychotic dopamine D2 affinity and negative symptoms in remitted first episode psychosis patients. Schizophr Res. 2024;274:299\u2013306. https:\/\/doi.org\/10.1016\/j.schres.2024.09.030.","journal-title":"Schizophr Res"},{"key":"713_CR44","first-page":"67","volume":"12","author":"JM Hope","year":"1951","unstructured":"Hope JM, Callaway E, Sands SL. Intravenous pervitin and the psychopathology of schizophrenia. Dis Nerv Syst. 1951;12:67\u201372.","journal-title":"Dis Nerv Syst"},{"key":"713_CR45","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/BF00432248","volume":"78","author":"B Angrist","year":"1982","unstructured":"Angrist B, Peselow E, Rubinstein M, Corwin J, Rotrosen J. Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology. 1982;78:128\u201330. https:\/\/doi.org\/10.1007\/BF00432248.","journal-title":"Psychopharmacology"},{"key":"713_CR46","doi-asserted-by":"publisher","first-page":"101337","DOI":"10.1016\/j.conctc.2024.101337","volume":"41","author":"N Zhand","year":"2024","unstructured":"Zhand N, Attwood D, Labelle A, Joober R, Robertson C, Harvey PD. Adjunctive methylphenidate extended release in patients with schizophrenia: protocol of a single-centre fixed dose cross-over open-label trial to improve functional and cognitive outcomes. Contemp Clin Trials Commun. 2024;41:101337. https:\/\/doi.org\/10.1016\/j.conctc.2024.101337.","journal-title":"Contemp Clin Trials Commun"},{"key":"713_CR47","first-page":"10","volume":"20","author":"LY Huey","year":"1984","unstructured":"Huey LY, Janowsky DS, Judd L, Whitehall W, Zetin M, Risch SC, et al. Effects of methylphenidate in adult psychiatric inpatients: a preliminary report. Psychopharmacol Bull. 1984;20:10\u20137.","journal-title":"Psychopharmacol Bull"},{"key":"713_CR48","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/BF02244317","volume":"105","author":"D Robinson","year":"1991","unstructured":"Robinson D, Mayerhoff D, Alvir J, Cooper T, Lieberman J. Mood responses of remitted schizophrenics to methylphenidate infusion. Psychopharmacology. 1991;105:247\u201352. https:\/\/doi.org\/10.1007\/BF02244317.","journal-title":"Psychopharmacology"},{"key":"713_CR49","first-page":"123","volume":"21","author":"JA Lieberman","year":"1985","unstructured":"Lieberman JA, Kane JM, Gadaletta D, Ramos-Lorenzi J, Bergmann K, Wegner J, et al. Methylphenidate challenge tests and course of schizophrenia. Psychopharmacol Bull. 1985;21:123\u20139.","journal-title":"Psychopharmacol Bull"},{"key":"713_CR50","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.euroneuro.2019.06.008","volume":"29","author":"F Corponi","year":"2019","unstructured":"Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, et al. Novel antipsychotics specificity profile: A clinically oriented review of Lurasidone, Brexpiprazole, Cariprazine and Lumateperone. Eur Neuropsychopharmacol. 2019;29:971\u201385. https:\/\/doi.org\/10.1016\/j.euroneuro.2019.06.008.","journal-title":"Eur Neuropsychopharmacol"}],"updated-by":[{"DOI":"10.1007\/s43440-025-00741-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000}}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00713-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00713-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00713-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T02:01:43Z","timestamp":1748656903000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00713-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["713"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00713-w","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s43440-025-00741-6","URL":"https:\/\/doi.org\/10.1007\/s43440-025-00741-6","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}